A biotechnology company, engages in the development and production of vaccines for pandemic and seasonal influenza diseases.
VaxInnate, Inc., a biotechnology company, engages in the development and production of vaccines for pandemic and seasonal influenza diseases. Its products include Flagellin.HuHA and flagellin.AvHA, which are fusion proteins linking a potent immune stimulator, the bacterial protein flagellin, with immunoprotective domain of viral hemagglutinin. The company's products are used in the treatment of various diseases, including bacterial, viral, and parasitic infections. VaxInnate, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.
|CHL Medical Partners||Series C||25th Oct 2006|
|CHL Medical Partners||Series D||Jun 2009|
|Canaan Partners||Venture capital firm with a focus on early stage technology and healthcare companies||Series C||25th Oct 2006|
|Healthcare Ventures LLC|
|MedImmune Ventures Inc||Series C||25th Oct 2006|
|New Leaf Venture Partners||Series C||25th Oct 2006|
|Oxford Bioscience Partners IV LP|
|Oxford Bioscience Partners||Series C||25th Oct 2006|
|Wellcome Trust||Series D||14th Jun 2009|
No current employees available
RECORD ID: 283507